glp-2
Small moleculeexperimental
Clinical trial activity
14 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00273000)
Timeline
Indications
Mechanism of action
GLP2R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- glp-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07254988 | N/A | Mar 24, 2023 | University of Copenhagen |
| NCT06194955 | N/A | Jan 4, 2023 | University of Copenhagen |
| NCT05181150 | N/A | Nov 16, 2021 | University of Copenhagen |
| NCT04651868 | N/A | Feb 28, 2021 | Novo Nordisk, University of Copenhagen |
| NCT03867656 | N/A | Feb 26, 2019 | University of Copenhagen |
| NCT03728959 | N/A | Sep 12, 2018 | University of Copenhagen |
| NCT03574064 | N/A | Jun 1, 2018 | University of Copenhagen |
| NCT03682172 | Early Phase 1 (Phase 1) | May 1, 2018 | Steno Diabetes Center Copenhagen |
| NCT03573934 | N/A | Sep 15, 2017 | University of Copenhagen |
| NCT03159741 | N/A | May 16, 2017 | University of Copenhagen |
| NCT01958775 | Phase 3 | Mar 1, 2012 | University of Toronto |
| NCT00673751 | N/A | May 5, 2008 | University of Copenhagen |
| NCT00732602 | N/A | Jan 31, 2008 | University of Copenhagen |
| NCT00273000 | N/A | Jan 1, 2006 | University of Copenhagen |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 12 | 12 | 1 | 2006 |
| Novo Nordisk | For profit | 1 | 0 | 1 | 2021 |
| Steno Diabetes Center Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2012 |
4 organizations
Page 1 / 1